CXCL12 and cancer: Using co-injection of KPC cancer cells and PSCs orthotopically in a syngeneic mouse model, Garg et al. demonstrated that PSCs secrete CXCL12 in the PDAC TME in an NF-ϏB-dependent manner, which leads to decreased infiltration of cytotoxic CD8+ T cells by binding to its receptor CXCR4, resulting in increased tumor growth [114].